Galen President and MD first keynote speaker in CEO Spotlight Series
Craigavon, N.I., 7 Oct 2019 - Dr. Dennise Broderick, President and Managing Director of global speciality pharmaceutical company, Galen, was the first member to participate in Northern Ireland Chamber of Commerce and Industry’s CEO Spotlight Series.
Supported by KPMG, the series, which was formally launched on Thursday 3rd October, aims to inspire business growth in local companies through exchanging leadership stories of successful entrepreneurs and senior managers.
The inaugural event took place at KPMG’s Soloist Building in Belfast and consisted of a business breakfast featuring a speech by Dr Broderick followed by a roundtable discussion where delegates could engage with each other and share insight, views and experiences with Dennise and other Chamber members.
Dennise, who was appointed to President and MD of Galen, a member of the Almac Group, in September 2018, started by sharing details of the company’s rich 50 year history and what has led to its global success. She then focused on her own career highlights, sharing details of her experience and skills, all of which has been instrumental in defining Galen’s new vision and goals.
The event was hugely successful with attendees thanking Dennise for her insight. Chamber member, Angus Cameron, Business Domain Lead, Air Operations & Weapons commented “Many thanks for a thought provoking and passionate account of business growth & transformation. It is good to know that be it the Pharma or Defence business, the key ingredients for profitable growth are the same.”
Dennise is a highly successful, respected and inspiring Executive Business Leader, with an extensive career within the pharmaceutical industry. She has held many Leadership positions within Ireland and Europe Targeted at senior business people and high potential young leaders, the three-part series is an opportunity for those at the forefront of local business to exchange views and learn from their peers in an intimate setting.
Pictured: Ann McGregor, Chief Executive, Northern Ireland Chamber of Commerce and Industry, Dr. Dennise Broderick, Managing Director Galen Ltd. and John Poole, Partner and Head of Audit, KPMG.
Notes to editors
Established in 1968, Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland), with products in therapy areas including gastroenterology, urology, female health, pain management and mental health.
As a subsidiary of Galen Limited, Galen US also has a growing presence in select conditions requiring topical anaesthesia and Central Nervous System disorders. The company plans to continue expanding its portfolio with selected specialty products on an international basis. By combining innovation in product development with competitive pricing, Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value. Visit: www.galen-pharma.com
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5,000 highly skilled personnel across 17 facilities including Europe, the US and Asia. Click here to view our facilities.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.
To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.